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Abstract
Background: Screening asymptomatic individuals for neoplasia can have adverse consequences on
quality of life. Colon cancer screening is widespread but the quality of life (QOL) consequences are
unknown. This study determined the impact of screening colonoscopy on QOL measures in
asymptomatic average-risk participants.
Methods: Asymptomatic male and female participants aged 55–74 years were randomly selected
from the Australian Electoral Roll or six primary care physicians' databases. Participants completed
the Short-Form (SF-36) Quality of Life Assessment at baseline and at a mean of 39 days after
colonoscopy. Outcome measures were (i) significant changes in raw scores in any of the eight SF-
36 domains assessed following colonoscopic screening and (ii) improvements or declines in
previously validated categories, representing clinically significant changes, within any of the eight SF-
36 domains.
Results: Baseline QOL measures were similar to those of a matched general population sample.
Role Limitations due to Emotions, Mental Health and Vitality raw scores significantly improved
following colonoscopy (P < 0.05, 2-tailed t-test). Health ratings according to Category were similar
(same clinical status) in the majority of participants. However, 30% participants recorded clinically
significant improvement in the Mental Health and Vitality domains (P < 0.05, Wilcoxon Signed-
Ranks test). This improvement was not offset by declines in other domains or in other participants.
Improvement in QOL was not related to colonoscopy results.
Conclusion:  Average-risk persons benefit significantly from colon cancer screening with
colonoscopy, improving in Mental Health and Vitality domains of Quality of Life. This improvement
is not offset by declines in other domains.
Background
Colorectal cancer is a common disease with a long lead-
time and easily recognised precursor lesions, making
screening a rational and effective means of prevention.
Colonoscopy from age 50 is accepted as an accurate and
cost-effective screening modality of colorectal cancer
screening, but is not yet the 'preferred' strategy [1,2].
The act of screening asymptomatic individuals for cancer
or precancerous lesions may result in health conse-
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quences, even in those not found to be screen-positive.
Potential consequences include increased anxiety,
reported among participants in screening for breast can-
cer, ovarian cancer, and prostate cancer [3-5]. However,
while there is evidence that colorectal cancer screening
may be the most effective form of cancer screening, there
is little published data regarding either adverse or benefi-
cial effects of screening on participants' health status. On
the other hand, severe adverse effects of screening by
colonoscopy, including haemorrhage and colonic perfo-
ration, are universally reported. While important, these
indicators are relatively rare events, with major procedure-
related morbidity in 0.3% [6]. Consequently, in an
attempt to determine the health consequences of colono-
scopic screening, we included a health-related quality of
life measure before and after screening in a study of 231
participants recruited from the Australian Electoral Roll
and primary care [7].
Methods
Criteria for selection of subjects
The study was originally designed to test the hypothesis
that recruitment for colonoscopic screening from general
practice would achieve better participation than recruit-
ment from the electoral roll. The sample size was based on
(i) the number of subjects aged 55–74 years needed to
achieve 100 to 125 colonoscopies in each of two arms and
(ii) the number of invitees to determine differences in
recruitment [7]. Asymptomatic, male and female partici-
pants aged 55–74 years were randomly selected from the
Australian Electoral Roll or six primary care physicians'
databases and invited by letter to participate in colorectal
cancer screening by colonoscopy. Participants were ineli-
gible for inclusion if they had gastrointestinal symptoms
requiring attendance at a primary care physician in the
previous 12 months, colonoscopy or barium enema
within the previous 10 years, significant co-morbidity
(American Society of Anesthesiologists class III or
greater), a prior diagnosis of cancer (not including non-
melanomatous skin cancer), previous colonic surgery, or
therapeutic anticoagulation.
Subjects attended the study site on three occasions. At
Visit 1, an information sheet was provided and written
consent for the study was obtained. We asked participants
about their medical history, including medications, fam-
ily history of cancer, and previous screening behaviour.
Eligibility criteria were assessed. At Visit 2 colonoscopy
was performed. All colonoscopy participants underwent a
physical examination to record their fitness for sedation.
Physician or nurse sedationists administered sedation
with a combination of fentanyl, midazolam and propo-
fol. At Visit 3, participants received results of the colonos-
copy and results of histopathology where relevant. We
sent a letter to the participant's primary care physicians,
summarising the results and a providing a recommenda-
tion for surveillance.
The study was conducted according to the National
Health & Medical Research Committee guidelines. The
Australian Capital Territory Human Research Ethics Com-
mittee and the Calvary Hospital Medico-Moral Human
Research and Ethics Committee approved the protocol
(10 December 2001).
Health assessment measures
Health-related quality of life was measured using the
Short Form-36 (SF-36) instrument version 1.8–9 SF-36
questionnaires were completed by the participants at Vis-
its 1 and Visit 3 with assistance from a Study Investigator.
Adverse events were assessed at Visit 2 and Visit 3. At Visit
3, colonoscopy findings were discussed and a recommen-
dation for repeat colonoscopy was made (five years for
first-degree relative with colorectal cancer or finding of
adenomatous polyp, ten years for normal findings and no
first-degree relative with colorectal cancer).
Statistical analysis
In addition to descriptive statistics, we carried out paired
t-tests comparing SF-36 scores before and after colonos-
copy. We performed ANOVA to examine the effect of
potential confounding factors on changes in SF-36 scores.
Potential confounding factors assessed were (i) finding of
adenomatous polyps at colonoscopy; (ii) presence of
adverse events, excluding failure to retrieve polyp; and
(iii) participants' ratings (0–100 on a Visual Analog Scale)
of discomfort and overall satisfaction with the procedure
[7]. We performed unpaired t-tests comparing partici-
pants' SF-36 scores to those of respondents from an inde-
pendent population survey [Shadbolt B and Craft PS.
Extending the use of the SF-36 in clinical practice. Health and
Quality of Life Outcomes, Accepted for Publication].
In comparing the pre- and post-SF-36 scores we also
employed 'clinically meaningful' cut points to interpret
the distributions obtained. Briefly, SF-36 data from an
Australian prospective cohort study of 5,668 hospital
patients [Shadbolt B and Craft PS. Extending the use of the
SF-36 in clinical practice. Health and Quality of Life Out-
comes, Accepted for Publication] were used to determine
Receiver-Operator curves in each SF-36 domain based on
known health states in these patients. Cut points were
applied to these Receiver-Operator curves to yield five cat-
egories (except the Role Physical domain, which has four
validated categories). These categories were retested
against raw data to confirm levels of sensitivity and specif-
icity to 'clinically poor' health and 'clinically good' health.
In the present study, movement by subjects between these
categories before and after colonoscopy were used to
determine whether or not a participant had a clinicallyHealth and Quality of Life Outcomes 2006, 4:82 http://www.hqlo.com/content/4/1/82
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worse or better SF-36 scale score after colonoscopy. Statis-
tical analysis was performed with SAS 9.1 (SAS Institute,
Cary NC). Incomplete data – data missing for one or more
domains of the SF-36 – was excluded from analysis of that
domain for that subject only.
Results
Patient characteristics
A total of 881 invitations were sent, 262 of those respond-
ing were assessed as ineligible to participate, and 231 had
a colonoscopy, yielding a participation rate in colonos-
copy of 37.3% [7]. The mean age of participants who had
a colonoscopy was 62 years (SD = 5), with 48% (110/231)
being females; 120 colonoscopy participants were drawn
from the electoral roll arm (49% female) and 111 from
the general practice arm, (46% female). The place of resi-
dence of study participants was classified according to the
six geographic divisions of the Australian Capital Terri-
tory; that of participants drawn from the Electoral Roll,
but not those drawn from General Practitioners, was
found to correspond closely with the population distribu-
tion in the Australian Capital Territory [7].
Colonoscopy results
Adenomatous and hyperplastic polyps were found in 104
(45%) subjects undergoing colonoscopy (Table 1). A total
of 30 minor adverse events were reported, and 2 serious
adverse events resulting in hospital admission, compris-
ing (i) bradycardia and (ii) vasovagal episode.
Health assessment
The screening assessment (Visit 1) at which the baseline
SF-36 scores were obtained was a mean of 30 days before
colonoscopy (median 23, range, 2–332). Visit 3, at which
the post-colonoscopy SF-36 scores were assessed, was a
mean of 36 days after colonoscopy (median 32 days,
range, 3–312). The mean time between Visits 1 and 3, and
therefore the mean time between the two measures of self-
rated wellbeing, was 68 days (median 56 days, range, 25–
365; standard deviation 34 days). A total of 225 SF-36
questionnaires were recorded for both Visits. Of these, 6
subjects had incomplete data in one or more domains.
One of these subjects had experienced an adverse event
(vasovagal episode) and data was incomplete in the Bod-
ily Pain scale only.
There were no significant differences between the SF-36
scores obtained before colonoscopy in our subjects and a
general population sample of a similar age range [Shadbolt
B and Craft PS. Extending the use of the SF-36 in clinical prac-
tice. Health and Quality of Life Outcomes, Accepted for Publi-
cation].
The physical health of subjects, as measured by the Physi-
cal Functioning Scale, was not significantly different after
colonoscopy (Table 2). Role Limitations due to Emotions
and Vitality scores of participants were significantly higher
following colonoscopy. There were no significant associa-
tions between changes in SF-36 scores and the finding of
adenomatous polyps at colonoscopy, presence of adverse
events, participants' rating of discomfort during the
colonoscopy or overall rating of satisfaction with the pro-
cedure (data not shown).
We next examined SF-36 rating scores according to prede-
termined categories. Most participants (range, 53.6% to
92.3%) were ranked in the same SF-36 category, signifying
similar clinical status, before and after colonoscopy (Fig-
ure 1). Approximately 20% of participants overall had
clinically worse scores (fall in category) after colonoscopy
and 20% had clinically better (rise in category) scores.
Table 1: Clinical outcomes of colonoscopy in 231 participants
N%
Subjects in whom polyps were identified 104 45.0
Subjects with advanced adenoma 8 3.5
Subjects with adenomatous polyps 74 32.0
Subjects with hyperplastic polyps 53 22.9
Any adverse events 33 14.3
Table 2: Raw SF-36 scores before and after colonoscopy
SF-36 Scale Mean Score
BEFORE
Mean Score
AFTER
N Difference of means 
(AFTER-BEFORE)
SD P value
PF: physical functioning 80.2 78.6 225 -1.6 15.5 0.13
BP: bodily pain 75.6 77.3 224 +1.7 21.6 0.23
RP: role limitations due to physical condition 82.6 85.2 219 +2.5 33.5 0.27
GH: general health perceptions 73.3 72.7 223 -0.5 12.2 0.51
SF: social functioning 88.1 88.5 223 +0.4 18.9 0.76
VT: vitality 64.6 66.5 224 +1.9 14.2 0.04*
RE: role limitations due to emotions 88.6 92.9 222 +4.4 28.8 0.03*
MH: mental health 78.0 79.9 224 +1.9 12.8 0.03*
SD = standard deviation; P value associated with two-tailed paired t test (*P < 0.05)Health and Quality of Life Outcomes 2006, 4:82 http://www.hqlo.com/content/4/1/82
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However, for the Role Limitations domain (Role Limita-
tion due to Physical Condition and Role Limitation due to
Emotions), more than 90% participants had similar
scores before and after colonoscopy.
Considerably more participants (30% overall) had clini-
cally better Vitality scores and Mental Health scores after
colonoscopy (Figure 1). This finding was statistically sig-
nificant (P < 0.05, Wilcoxon Signed-Rank Test).
We next examined relationships between clinical out-
comes and QOL outcomes by category. There was no asso-
ciation between finding of adenomatous polyps at
colonoscopy, presence of adverse events, or participants'
overall rating of satisfaction with the procedure, and
improvements or declines in category (data not shown).
Discussion
Screening for cancer creates an increased level of duty for
healthcare providers. Most patients having the screening
test will not have the disease and will not benefit directly
from the test. They may be harmed by a false-positive
result or if the test causes injury. However, bowel cancer is
an ideal disease for screening, with high lifetime incidence
and prevalence in the screening age range [10], and being
severe, detectable and curable with low morbidity at early
stages of disease. Screening by colonoscopy is invasive
and may cause haemorrhage in 1:500 patients and colonic
perforation in 1:2000 [6] but has high specificity and low
false-positive rate for cancer [10]. Because few will be
harmed as a result of colonoscopic screening, any benefi-
cial effects should be assessable. In contrast, any beneficial
effects of other forms of colon cancer screening, such as
faecal occult blood tests [11] might be obscured by the
detrimental effect of a false-positive test, and the lack of
confidence in a negative test. Therefore, we reasoned that
quality-of-life assessment should be valid and meaningful
after a single episode of colorectal cancer screening by
colonoscopy.
In this study, asymptomatic, randomly selected partici-
pants having colonoscopic screening for colorectal cancer
were surveyed for Health-related Quality of Life using the
SF-36 before and after the screening colonoscopy. Aggre-
Percentage of CRC screening participants who had clinically worse (pale bars) or better (dark bars) SF-36 ranked scale scores  after colonoscopy Figure 1
Percentage of CRC screening participants who had clinically worse (pale bars) or better (dark bars) SF-36 ranked scale scores 
after colonoscopy. P value was obtained from Wilcoxen Signed Ranks Test, using matched pairs of category comparisons 
before and after colonoscopy.
p value 0.44     0.61         0.68 0.81    0.50       0.003        0.09 0.001
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gate data showed significant positive changes in SF-36
scores in the Mental Health, Role Limitations due to Emo-
tions, and Vitality domains (Table 2). These measures do
not indicate that the changes are clinically meaningful.
Furthermore, numerical gains or losses from differing
baselines are not necessarily equally weighted [12]. To fur-
ther interpret these changes we examined SF-36 rating
scores according to previously validated categories. These
categories were constructed from an inpatient population
with overall lower health status than our outpatient
cohort, and were then validated in groups of patients with
acute health conditions [Shadbolt B and Craft PS. Extending
the use of the SF-36 in clinical practice. Health and Quality of
Life Outcomes, Accepted for Publication]. Therefore, findings
from Category analysis in the present study need to be
interpreted with caution, but may serve to confirm and
extend the results of aggregate data.
Nearly all participants had clinically similar Role Limita-
tion Category scores (Figure 1) before and after colonos-
copy, and while more participants showed significant
gains than significant declines in Role Limitations due to
Emotions, the number benefiting was small. Other
domains exhibited more volatility, with approximately
40% of participants changing categories. The most con-
spicuous result was the 30% of participants reporting clin-
ically meaningful gains in Vitality and Mental Health
scores (Figure 1), confirming the results of raw-score anal-
ysis. Comparison of raw-score analysis and category anal-
ysis saw the improvement seen in Role Limitation due to
Emotions (difference of means 4.4, P = 0.03 for two-tailed
t-test) to be not statistically significant in Category analy-
sis (P = 0.09).
Adenomatous polyps are rarely symptomatic. Therefore,
even if subjects had a polypectomy at the screening exam-
ination, they could not be expected to improve in physical
wellbeing. Indeed, in this study there were no improve-
ments in the physical health domains of the QOL, irre-
spective of colonoscopy result. On the other hand, some
subjects receiving good news might be expected to report
improvements in mental health or emotional wellbeing.
This was observed in the present study.
This is the first report of participants in a cancer screening
program reporting an overall improvement in health rat-
ings after the test. For example, men with a family history
of prostate cancer were assessed before and after screening
by prostate-specific antigen [5]. A third of these subjects
reported a decline in more than 2 times the standard error
in at least one dimension of the QOL scale. The mental
component summary of the SF-36 scale exhibited an over-
all decline in participants in an ovarian cancer screening
program [13]. In that study, participants were at increased
risk of ovarian cancer and 38.5% of participants had a
positive screening test.
Our study had some limitations. The second measure of
QOL was generally performed within five weeks after the
procedure, so the durability of any beneficial effect cannot
be ascertained. We performed no measures of physical or
mental functioning on participants, so we cannot deter-
mine whether the reported QOL gains were meaningful
for these individuals. The results may have been subject to
bias: the Authors are enthusiasts of colon cancer screening
and may have unwittingly promoted colon cancer screen-
ing at interviews [14]. While the SF-36 scores obtained at
the first visit did not differ from population norms, we
cannot guarantee that they are 'baseline' for these individ-
uals, and these initial scores may have reflected stresses
induced by contact with an unfamiliar environment and
medical staff. Therefore, any improvements may have
reflected regression to the mean. Our results may only be
relevant to our local population. The Australian Capital
Territory has a relatively well-educated, high-income pop-
ulation [15] that may respond differently to other popula-
tions, although the SF-36 instrument itself is reported to
be a robust tool across differing populations and lan-
guages [16].
Conclusion
Average-risk persons participating in colon cancer screen-
ing with colonoscopy obtain a significant benefit, with
improvements in Mental Health and Vitality domains of
QOL. This improvement is not offset by declines in other
domains of the QOL. If our observations can be repro-
duced in different populations, the improvement seen in
quality of life after screening colonoscopy could represent
a persuasive argument for screening for this type of cancer
and using this modality. It would therefore be useful to
confirm these findings in additional, prospective studies,
performed in the average-risk population of different
regions.
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